InduPro
Rob Oslund has a strong work history in the field of platform technology and chemical biology. Rob started their career as an NIH Postdoctoral Fellow at Princeton University, where they worked in the Tom Muir Lab. In 2016, they joined Neon Therapeutics as a Peptide Chemistry and Biochemistry Scientist. Rob then moved to Merck in 2017, where they held roles as a Chemical Biologist and later as the Cellular Chemistry & Platform Technology Lead. Currently, they are working at InduPro as the VP of Platform Technology.
Rob Oslund earned a Bachelor of Science degree in Chemistry from Southern Utah University from 1999 to 2005. Following this, they pursued a Ph.D. in Biological Chemistry at the University of Washington, where they worked in the Mike Gelb Lab, specializing in the same field.
This person is not in any offices
InduPro
InduPro is bringing life-changing therapies to patients through novel cell-surface platform technologies. We are defining and manipulating protein interactions beyond natural signaling paradigms. InduPro platforms, integrate inherent protein proximity at the cell surface with the ability to manipulate protein pairings via induced protein proximity to create novel signaling pathways and logic gates.